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Effects of right ventricular dysfunction on exercise capacity and 
quality of life and associations with serum NT-proBNP levels in COPD: 
an observational study
ABSTRACT
Objective: During the course of chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH) and right ventricular (RV) failure 
may develop due to elevated afterload of the RV. In those patients, exercise capacity is reduced due to pulmonary and cardiac limitations. We 
investigated relationships between serum N-terminal of proB-type natriuretic peptide (NT-proBNP) and RV functions with exercise capacity 
and quality of life in patients COPD.
Methods: An observational case-control study was conducted. We enrolled 31 moderate and severe COPD patients, and 20 subjects without 
chronic diseases as control group. Parameters reflecting the right ventricular diastolic and systolic functions by echocardiography along with 
serum NT-proBNP levels were assessed. Cardiopulmonary exercise testing and Short Form-36 (SF-36) were applied. 
Results: Serum NT-proBNP levels were higher in COPD patients than control group (p=0.003). Serum NT-proBNP level was found to be related 
with pulmonary arterial pressure. Serum NT-proBNP levels were negatively correlated with anaerobic threshold oxygen uptake (AT VO2) and 
peak oxygen uptake (PVO2) values. Early ventricular filling velocity (Em) was lower in COPD patients. Em wave was significantly correlated with 
O2 pulse. There was a positive relationship between tricuspid E/A ratio and VO2 value at AT. SF-36 domains of physical functioning, general 
health and role limitation due to physical disorder were significantly correlated with AT VO2, PVO2 and O2 pulse. 
Conclusion: Exercise limitation may be predicted by assessment of right ventricule functions and NT-proBNP levels and exercise limitation impairs 
quality of life in COPD patients. (Anadolu Kardiyol Derg 2014; 14: 370-7)
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major 
cause of morbidity all over the world and characterized by irre-
versible airway obstruction (1). Impaired exercise capacity can 
result from ventilatory limitation, respiratory muscle weakness 
and abnormal gas exchange together with cardiac limitation in 
COPD patients. Pulmonary hypertension and right heart failure 
may develop in the course of COPD. Pulmonary hypertension (PH) 
with increased right ventricle load, failure and elevated pulmo-
nary vascular resistance is a cause of early death. Development 
of PH is also associated with poor quality of life and exercise 
limitation. Diastolic dysfunction is defined as inconvenient 
increase in right ventricle diastolic pressure with insufficient fill-
ing of right ventricle. Right ventricular dysfunction can be seen 
before the development of pulmonary hypertension and cor pul-
monale in COPD patients (2-4). 
N-terminal of proB-type natriuretic peptide (NT-proBNP) 
is a precursor of brain natriuretic peptide (BNP). Measurement 
of NT-proBNP level is more reliable than measurement of 
BNP due to the short half life of BNP. N-terminal proB-type 
natriuretic peptide (NT-proBNP) is an important and helpful 
indicator in differentiating congestive heart failure from lung 
diseases (5). However, elevated NT-proBNP levels have been 
found in patients with COPD and in patients with right ven-
tricular dysfunction (6, 7). Moreover, increased NT-proBNP 
levels can be seen in many diseases such as left ventricular 
dysfunction, right ventricular dysfunction secondary to pul-
monary diseases, infectious diseases, endocrinological dis-
orders, and high output status without decreased left ven-
tricular ejection fraction (8). Therefore measurement of 
NT-pro BNP levels can also be useful in the diagnosis of 
impaired right ventricular functions in COPD patients. 
Dyspnea is a major symptom limiting exercise capacity in 
COPD patients (1). Cardiopulmonary exercise testing is a nonin-
vasive tool in the diagnosis of pulmonary and cardiovascular 
diseases and also helps to determine disease severity. 
Although significance of serum NT-proBNP in COPD patients 
has been investigated previously, there has been no study inves-
tigating the relationship between serum NT-proBNP and exer-
cise capacity in COPD patients according to our knowledge. We 
hypothesize that serum NT-proBNP level might indicate impaired 
right ventricular functions, quality of life and exercise limitation 
in COPD patients. 
The goal of this study was to investigate relationships 
between serum NT-proBNP level and right ventricular functions 
with exercise capacity and quality of life in patients with COPD.
Methods
A case control observational study was designed. The Ethics 
Committee of our university certified the study protocol and 
study was conducted within research project as KA09/274. 
Study population
Patients with COPD followed in department of pulmonary 
diseases outpatient clinic between August 2009 and August 2010 
were consecutively included. All participants provided informed 
consent. COPD was diagnosed based on the criteria defined in 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines (1). 
Thirty-one patients with moderate, severe and very severe 
COPD patients during stable period and 20 healthy individuals 
were recruited to the study. Subjects in the control group were 
older than 40 years of age without any medical disorders. 
COPD patients during acute exacerbation period, patients 
with asthma, hypoxia, pneumonia, left ventricular systolic dys-
function, valvular pathology, arrhythmia, renal failure, diffuse 
parenchymal lung diseases, lung carcinoma and other malig-
nancies, neuromuscular disorders affecting exercise capacity 
and subjects younger than 40 years of age were all excluded 
from the study. 
Study protocol
Pulmonary function tests, echocardiography, plasma NT-pro 
BNP measurement, CPET and short form-36 (SF-36) question-
naire were performed to all subjects. 
Pulmonary function tests
Pulmonary function tests (PFTs) were performed with a 
clinical spirometer (SensorMedics Vmax spectra 229, Bilthoven, 
The Netherlands). Maximal expiratory flow maneuver was per-
formed by patients and control subjects. Forced expiratory vol-
ume at 1 second (FEV1) and forced vital capacity (FVC) values 
were obtained and FEV1/FVC was calculated. Standard PFTs 
including spirometry and lung volumes were evaluated accord-
ing to the previously described guidelines (9). Patients with post-
bronchodilator FEV1 <80% of predicted value, FEV1/FVC <70%, 
and irreversible airflow obstruction were recruited to the study 
(10). Post-bronchodilator FEV1 values were used to define dis-
ease stage according to the GOLD severity classification.
Echocardiography 
Tissue Doppler and 2-dimensional echocardiographic mea-
surements of 31 patients with moderate, severe and very severe 
COPD patients during stable period and 20 healthy individuals 
were carried out in the supine position according to the recom-
mendations of American Society of Echocardiography with 
Acuson Sequoia C-256 (Acuson Corporation, California, USA) 
cardiac ultrasound machine and 3.5 MHz probe (11). Apical 
4-chamber, and parasternal long-axis views were obtained. The 
left ventricular ejection fraction (EF%) was calculated using the 
modified Simpson’s rule (12). 
Mean pulmonary arterial pressure (PAP) was figured out by the 
formula of 79- (0.45X pulmonary artery acceleration time) (13, 14).
Right ventricular diastolic velocities were obtained by using 
pulsed tissue Doppler imaging [early ventricular filling -early 
diastolic wave (Em) and late diastolic wave during atrial con-
traction (Am)]. Peak early (E) and late (A) diastolic velocities of 
tricuspid valve were recorded during apical 4-chamber view. 
Assessment of right ventricular (RV) diastolic function was car-
ried out by pulsed Doppler of the tricuspid inflow and tissue 
Doppler of the lateral tricuspid annulus. Grading of RV diastolic 
dysfunction was performed. Patients with tricuspid E/A ratio 
<0.8 was determined as grade 1 RV diastolic dysfunction and a 
tricuspid E/A ratio of 0.8 to 2.1 with an E/e’ ratio >6 as grade 2 RV 
diastolic dysfunction (pseudonormal filling). We had no subject 
with a tricuspid E/A ratio >2.1 with deceleration time <120 ms. 
Tricuspid Annular Plane Systolic Excursion (TAPSE) - was mea-
sured from the tricuspid lateral annulus (15, 16).
Cardiopulmonary exercise test 
Cycle ergometer (Ergo-metrics 900; SensorMedics Bilthoven, 
The Netherlands) was used for cardiopulmonary exercise test 
(CPET). All subjects underwent symptom-limited exercise with a 
facemask (Rudolph Face Mask for Exercise Testing; Hans 
Rudolph Inc., Kansas City, MO, USA) fixed on face. After three-
min baseline resting period records, a three-min warm-up peri-
od (60 rpm was the maintainance pedaling rate) was started. 
And then incremental work (10-15 W elevation for each minute) 
was applied (17). An automated exercise testing system (Desktop 
Diagnostics/CPX; Medical Graphics Corporation, St. Paul, MI, 
USA) was used for collecting data. The maximum work rate for 
half a minute was saved. During CPET, continious monitorization 
of 12 lead electrocardiography, blood pressure, and pulse oxy-
gen saturation was performed. Peak oxygen uptake (PVO2 mL/
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kg/min), peak CO2 output, and VE/VCO2 values were evaluated. 
The two-slope method was used to determine anaerobic thresh-
old (AT L/min). The equation of Wasserman et al. (17) was used 
to determine age-predicted values. Symptoms like fatigue, dys-
pnea, dizziness for ending the test were also noted. 
The SF-36 questionnaire
The SF-36 questionnaire was used to evaluate quality of life 
(QOL) (18, 19). This questionnaire has been validated for COPD 
patients previously. The subjects’s daily routine activities, social 
life and exercise performance were determined with 36 ques-
tions of this item. Main eight domains as physical function, 
social function, physical and emotional role function, mental 
health, bodily pain, vitality, and general health perception were 
found. A computer algorithm was used to score the responses 
to the SF-36 (20).
NT-proBNP measurement 
Blood samples were drawn in tubes containing EDTA. 
Plasma NT-proBNP was measured with electrochemilumines-
cence immunoassay on an Elecsys 2010 system (Roche 
Diagnostics, Mannheim, Germany). NT-proBNP concentrations 
were measured as pg/mL. Serum NT-proBNP was evalauted as 
normal when below 84 pg/mL for males and 155 pg/mL for 
females. 
Statistical analysis
Statistical analysis was accomplished using SPSS (SPSS ver-
sion 20.0; SPSS Inc., Chicago, IL, USA). Data was expressed as 
mean values±SD and median (range min-max) for continious vari-
ables, percentage for categorical variables in descriptive analysis. 
Distribution of continuous variables were checked with Shapiro-
Parameters COPD patients Control subjects P
FEV1/FVC 47.19±10.76 78.20±5.73 0.000
FEV1, L 1.60±0.47 3.73±0.74 0.000
FEV1, % 56.77±13.10 120.1±14.47 0.000
FVC L 3.59±0.90 4.86±0.94 0.000
FVC, % 98.32±13.77 130.7±16.19 0.000
FEF25-75, % 17.16±8.27 92.55±28.58 0.000
TLC L 6.55±1.62 6.55±1.17 0.998
TLC, % 106.42±21.27 120.85±12.88 0.004
VC L 3.60±0.90 4.86±0.94 0.000
VC, % 96.48±14.99 125.30±17.50 0.000
RV L 2.96±1.04 1.90±0.36 0.000
RV, % 133.42±48.45 104.40±17.29 0.050
IC L 2.18±0.68 3.14±0.65 0.000
MVV 69.03±31.73 129.80±34.66 0.000
AT VO2 mL/kg/min 13.32±4.04 19.57±5.12 0.000
AT VO2 L/min 1.01±0.35 1.46±0.41 0.000
AT VCO2 1.05±0.36 1.51±0.43 0.000
AT VEO2 38.14±7.48 31.55±4.59 0.000
AT VECO2 36.76±7.21 31.05±4.33 0.000
PVO2 L/min 1.26±0.38 1.87±0.46 0.000
PVO2  mL/kg/min 16.93±3.86 24.69±4.86 0.000
PVCO2 L/min* 1.46 (0.56-11.2) 2.24 (1.25-3.32)  0.000
PVEO2 1.74±1.83 2.26±0.60 0.000
VE/VCO2 33.19±8.38 30.89±4.10 0.148
PET CO2 4.66±0.72 4.66±0.55 0.981
Breathing reserve 20.69±22.17 60.79±27.68 0.000
Pulse reserve 38.48±15.79 50.65±30.30 0.288
O2 pulse 11.13±4.00 18.71±8.57 0.001
Exercise duration, sec 257.42±108.93 400.0±154.10 0.000
Serum NT-proBNP (pg/mL) 100.03±82.40 48.25±34.87 0.003
RV EF, % 47.52±5.16 51.15±3.96 0.206
RV diastolic diameter 33.34±8.15 33.55±5.30 0.189
RV systolic diameter 17.03±4.86 17.06±3.04 0.282
Em 9.88±2.60 14.90±4.87 0.360
Am 13.85±3.68 15.74±5.25 0.081
Em/Am ratio 0.71±0.18 0.95±0.20 0.471
TAPSE 2.26±0.46 2.64±0.38  0.040
Tricuspit  E 50.55±12.51 55.45±8.63  0.176
Tricuspit A 51.77±10.57 47.95±8.57 0.131
E/A 0.99±0.25 1.16±0.18 0.907
RA diameter 3.35±0.41 3.19±0.25 0.658
Table 2. Pulmonary function test, cardiopulmonary exercise testing, 
serum NT-proBNP. echocardiography and SF-36 results of study 
population
 COPD patients Control subjects  
 (n=31) (n=20) P
Age, mean±SD, years* 61.2±7.5 59.3±7.0 0.671
Gender F/M n (%)** 3 (9.7) / 28 (90.3) 8 (40) / 12 (60) 0.015
Weight (mean±SD)*, kg 74.4±17.2 75.4±12.8 0.831
Height (mean±SD)*, cm 166.9±8.4 165.9±7.1 0.645
BMI (mean±SD)*, kg/m2 26.5±4.6 27.3±3.9 0.508
Pack year (mean±SD)* 48.5±16.0 26.4±18.0 0.001
Smoking history n (%)**
Active smoker 12 (38.7) 6 (30.0) 
Ex-smoker 17 (54.8)  5 (25.0)  0.004
Never smoked 2 (6.5) 9 (45.0) 
Data was expressed as mean values±SD for age, weight, height, BMI and pack year. 
Data was expressed as percentage for gender and smoking history.
BMI - body mass index; COPD - chronic obstructive pulmonary disease;  F/M - female/male
*Student’s t-test.
**Pearson chi-square test and Fisher Exact test.
Table 1. Demographic data of study population
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Wilk test. Homogenity of variances was analysed with Levene test. 
Mean of two groups with normally distributed variances were 
compared with Student’s t test. Comparisons of parameters with-
out normal distribution between two groups were made by Mann-
Whitney U test. Pearson chi-square test and Fisher exact test were 
used for the analysis of categorical variables. Spearman rho cor-
relation coefficient was used to determine correlations between 
parameters without normal distribution and Pearson correlation 
coefficient was used to determine correlations between parame-
ters with normal distribution. P<0.05 was accepted as significant. 
Results
Baseline characteristics
Demographic data of study population is demonstrated at 
Table 1. There was significant difference between patient and 
control groups in terms of smoking status (p=0.004). No signifi-
cant statistical difference was found in terms of body mass 
index of patient and control group (p=0.508). 
Pulmonary function tests and CPET results
FEV1 (liter and %), FVC (liter and %), FEV1/FVC ratio, TLC (%), 
VC (liter and %), FEF25-75 (%) and MVV values were decreased in 
patient group significantly (p=0.000) (Table 2).
We found significant differences between patient and control 
groups in terms of AT VO2, AT VCO2, AT VEO2, AT VECO2 values, 
PVO2,VE, breathing reserve, O2 pulse and exercise duration 
(p=0.000) (Table 2). Serum NT-proBNP values were significantly 
higher in COPD patients than control group (mean serum NT-proBNP: 
100.03±82.40; 48.25±34.87 respectively, p=0.000) (Table 2).
Echocardiographic assessment results
Echocardiographic assessment results are demonstrated at 
Table 2. TAPSE values were significantly different between 
RV diameter 2.98±0.29 2.74±0.30 0.973
mean PAP*, mm Hg 35 (30-55)
Physical functioning* 75 (15-100) 97.5 (50-100) 0.000
Mental health 61.62±17.88 68.18±15.30 0.474
General health 49.94±18.24 71.95±10.51 0.518
Vitality* 66.5 (20.5-90) 74.7 (30.5-100) 0.037
Role limitation due to an 100 (0-100) 100 (50-100) 0.018 
emotional disorder *
Pain* 100 (12-100) 100 (41-100) 0.036
Social functioning* 100 (25-100) 100 (50-100) 0.092
Role limitation due to  66.6 (0-100) 88.8 (0-100) 0.04 
a physical disorder*
Data was expressed as mean±SD for parameters with normal distribution and *median for 
parameters with skewed distribution (range min-max).
*Comparisons of these parameters between two groups were made by Mann-Whitney U test.
Other parameters of two groups were compared with Student’s t-test.
Am - late diastolic wave during atrial contraction; AT - anaerobic threshold; CPET - 
cardiopulmonary exercise test; COPD - chronic obstructive pulmonary disease; Em - early 
diastolic wave; FEF25-75% - forced expiratory flow at 25-75%; FEV1 - forced expiratory volume 
at 1 second; FVC - forced vital capacity; IC - inspiratory capacity; MVV - maximum voluntary 
ventilation; NT-pro BNP - N-terminal of pro B-type natriuretic peptide; PAP - pulmonary 
arterial pressure; PET CO2 - partial pressure of end-tidal carbon dioxide; PVCO2 -  peak CO2 
output, PVO2-peak oxygen uptake; RA diameter - right atrium diameter; RV diameter - right 
ventricle diameter; RV EF - right ventricle ejection fraction; RV - residuel volume; SF-36 - short 
form-36; TAPSE - tricuspid annular plane systolic excursion; TLC - total lung capacity; VC - 
vital capacity; VECO2 - ventilatory equivalent for CO2; VEO2 - ventilatory equivalent for O2.
 NT-Pro BNP
Parameters rho P
mean PAP*  0.651 0.016
Tricuspit E -0.126 0.377
Tricuspit A 0.090 0.530
E/A -0.186 0.190
TAPSE 0.005 0.974
Em -0.154 0.281
Am 0.068 0.635
Em/Am rate -0.182 0.202
RV EF% -0.093 0.514
RA diameter 0.079 0.584
RV diameter 0.185 0.194
RV diastolic diameter 0.140 0.329
RV systolic diameter 0.111 0.438
Cigarette pack year 0.354 0.025
Age 0.422 0.002
FEV1 L -0.439 0.001
FEV1, % -0.269 0.049
FVC, % -0.295 0.035
IC L -0.407 0.003
VC L -0.544 0.000
AT VO2 mL/kg/min -0.462 0.001
AT VO2 L/min -0.372 0.008
AT VCO2 -0.372 0.008
PVO2 L/min -0.441 0.001
PVO2 mL/kg/min -0.527 0.000
O2 pulse -0.388 0.005
VE/VCO2 -0.041 0.776
PET CO2 0.071 0.621
*Spearman Correlation analysis was performed.
Other correlations were performed with Pearson Correlation Analysis
Am - late diastolic wave during atrial contraction; AT - anaerobic threshold; CPET -   
cardiopulmonary exercise test; COPD - chronic obstructive pulmonary disease; Em - early 
diastolic wave; FEV1 - forced expiratory volume at 1 second; FVC - forced vital capacity; IC - 
inspiratory capacity; MVV - maximum voluntary ventilation; NT-pro BNP - N-terminal of pro 
B-type natriuretic peptide; PAP - pulmonary arterial pressure; PET CO2 - partial pressure of 
end-tidal carbon dioxide; PVCO2 - peak CO2 output, PVO2 - peak oxygen uptake; RA 
diameter - right atrium diameter; RV diameter - right ventricle diameter; RV EF - right 
ventricle ejection fraction; TAPSE - tricuspid annular plane systolic excursion; VC - vital 
capacity; VECO2 - ventilatory equivalent for CO2, VEO2 - ventilatory equivalent for O2.
Table 3. Relationships between NT-proBNP level with smoking, age, 
pulmonary function test, echocardiography, and cardiopulmonary 
exercise testing results in COPD patients
Özdemirel et al.
Right ventricular dysfunction and exercise capacityAnadolu Kardiyol Derg 2014; 14: 370-7 373
patient and control groups (2.26±0.46 cm; 2.64±0.38 cm respec-
tively, p=0.040). Moreover COPD patients had reduced right 
ventricular Em wave, Em/Am ratio and tricuspit E wave (Table 2). 
When we graded right ventricle diastolic dysfunction in study 
population, 6 (19.3%) COPD patients had grade 1 right ventricle 
diastolic dysfunction, 8 (54.8%) COPD patients had grade 2 dia-
stolic dysfunction and the rest of COPD patients and control 
subjects had normal right ventricle diastolic functions. 
SF-36 results
Domains of role limitation due to an emotional disorder, pain 
and role limitation due to a physical disorder were significantly 
different between patient and control groups (Table 2).
Correlation analyses
When we correlated serum NT-proBNP level of COPD 
patients with cigarette consumption, pulmonary arterial pres-
sure, pulmonary function test, cardiopulmonary exercise testing, 
echocardiographic assessments, we found negative correla-
tions between serum NT-proBNP level with pulmonary function 
test results, AT VO2, AT VCO2, PVO2, and O2 pulse; positive cor-
relations between serum NT-proBNP level with pulmonary arte-
rial pressure and cigarette consumption (Table 3).
There were significant correlations between FEV1 (liter) with 
Em, Am, Em/Am ratio, TAPSE, tricuspit E, E/A ratio and right ven-
tricle diameter; IC and VC (liter) with Em, Am waves, Em/Am ratio 
and TAPSE values in COPD patients (Table 4). We also found sig-
Echocardiographic  FEV1 liter O2 pulse PVO2 mL/kg/min AT VO2 L/min
parameters rho P rho P rho P rho P
PAP* -0.138 0.653 -0.244 0.423 -0.436 0.136 -0.290 0.361
RV % EF 0.349 0.012 0.382 0.034 0.106 0.572 0.190 0.324
RV diastolic diameter 0.133 0.353 0.103 0.582 -0.144 0.440 0.162 0.401
RV systolic diameter 0.144 0.313 0.080 0.670 -0.155 0.405 0.173 0.369
Em 0.610 0.000 0.357 0.049 0.007 0.969 0.261 0.172
Am 0.393 0.004 0.266 0.148 0.043 0.818 -0.008 0.965
Em/Am ratio 0.421 0.002 0.171 0.359 -0.017 0.928 0.291 0.125
TAPSE 0.466 0.001 0.287 0.118 0.002 0.993 0.233 0.224
Tricuspit E 0.344 0.013 0.231 0.212 -0.092 0.623 0.381 0.042
Tricuspit A -0.078 0.587 0.031 0.867 -0.069 0.711 -0.200 0.299
E/A 0.348 0.012 0.227 0.219 0.001 0.994 0.569 0.000
RA diameter -0.130 0.363 0.187 0.315 0.046 0.805 0.221 0.249
RV diameter -0.333 0.017 -0.003 0.989 -0.149 0.425 0.202 0.294
*Spearman correlation analysis was performed.
Other correlations were performed by using Pearson correlation analysis 
Am - late diastolic wave during atrial contraction; AT - anaerobic threshold; COPD - chronic obstructive pulmonary disease; Em - early diastolic wave;  FEV1 - forced expiratory 
volume at 1 second; NT-pro BNP-N-terminal of pro B-type natriuretic peptide; PAP - pulmonary arterial pressure; PVO2 - peak oxygen uptake; RA diameter - right atrium diameter; RV 
diameter - right ventricle diameter; RV EF - right ventricle ejection fraction; TAPSE - tricuspid annular plane systolic excursion
Table 4. Relationships between right ventricular findings with FEV1 and cardiopulmonary exercise testing results in COPD patients.
 FEV1 lt IC AT VO2 L/min PVO2 L/dk O2 pulse NT- pro BNP
SF-36 rho P Rho P rho P rho P rho P rho P
Physical functioning* 0.688 0.000 0.538 0.000 0.522 0.000 0.520 0.000 0.445 0.001 -0.196 0.168
Mental health** 0.230 0.105 0.157 0.271 0.128 0.382 0.204 0.150 0.169 0.236 -0.083 0.562
General health** 0.614 0.000 0.338 0.015 0.450 0.001 0.487 0.000 0.374 0.007 -0.101 0.24
Vitality* 0.368 0.008 0.355 0.010 0.185 0.202 0.255 0.070 0.304 0.030 -0.219 0.12
RL due to ED* 0.403 0.003 0.376 0.007 0.212 0.145 0.372 0.007 0.404 0.003 -0.225 0.113
Pain* 0.305 0.030 0.257 0.049 0.125 0.392 0.258 0.068 0.234 0.098 -0.190 0.181
Social functioning* 0.218 0.124 0.135 0.345 0.190 0.192 0.199 0.162 0.064 0.653 -0.01 0.94
RL due to PD* 0.403 0.003 0.327 0.019 0.271 0.060 0.412 0.003 0.354 0.011 -0.324 0.02
**Pearson correlation analysis was performed. 
*Spearman Correlation analysis was performed.
AT - anaerobic threshold; COPD - chronic obstructive pulmonary disease; ED - emotional disorder; FEV1 - forced expiratory volume at 1 second; IC - inspiratory capacity; NT-pro BNP- 
N - terminal of pro B-type natriuretic peptide; PD - physical disorder; PVO2 - peak oxygen uptake; RL - role limitation; SF-36 - short form-36
Table 5. Relationship between SF-36 questionnaire with pulmonary function tests, cardiopulmonary exercise tests and serum NTpro-BNP in 
COPD patients
Özdemirel et al.
Right ventricular dysfunction and exercise capacity Anadolu Kardiyol Derg 2014; 14: 370-7374
nificant relationships between O2 pulse with right ventricle EF and 
Em wave; AT VO2 (L/min) with tricuspit E wave and E/A ratio; AT 
VEO2 with right ventricle diameter (Table 4). 
There were significant relationships between FEV1 and IC 
with SF-36 domains (Table 5). SF-36 domains of physical function-
ing, general health and role limitation due to physical disorder 
were significantly correlated with AT VO2, PVO2 and O2 pulse. 
Moreover we found significant relationship between role limita-
tion due to emotional disorder with PVO2 and O2 pulse. Mental 
health, pain and social functioning domains with cardiopulmonary 
exercise testing results were not significantly correlated (Table 5). 
A negative correlation between serum NT-proBNP level with role 
limitation due to physical disorder was found (p=0.02; r=-0.324) 
(Table 5).
Discussion
The present study demonstrated significant correlations 
between serum NT-proBNP level with role limitation due to 
physical disorder and CPET parameters in COPD patients sup-
porting our hypothesis. 
In the present study, early diastolic filling (E wave), right 
ventricle myocardial early filling (Em), and ratio of Em/Am were 
decreased in COPD patients and TAPSE values were signifi-
cantly lower in COPD patients than control subjects suggesting 
the impaired systolic and diastolic functions of COPD patients. 
Karabulut et al. (21) found deterioration of right ventricular 
diastolic functions with progressed disease stage of COPD 
patients and highlighted the importance of echocardiographic 
assessments in COPD patients. In parallel with these findings 
we found significant correlations between FEV1 with Em wave, 
Em/Am ratio, TAPSE, tricuspit E wave and E/A ratio in COPD 
patients. According to these results, we consider that right 
ventricle systolic and diastolic functions were adversely 
affected with disease progression. 
In COPD patients, right ventricular wall tension causes the 
release of BNP. Therefore increased serum BNP level has been 
defined as a powerful marker in diagnosis and severity of PH (22). 
Increased serum BNP levels have also been reported in patients 
with PH secondary to acute and/or chronic respiratory diseases 
(23) In the present study, serum NT-proBNP levels were signifi-
cantly higher in COPD patients than control subjects. In previous 
studies, Lang et al. (24) and Chi et al. (25) reported higher BNP 
levels in COPD patients than control subjects. Bozkanat et al. 
(26) and Chi et al. (25) showed the significant relationships 
between serum NT-proBNP with FEV1 in COPD patients. In the 
present study we determined significant negative correlations 
between serum NT-proBNP with FEV1, FVC, IC and VC as well. 
Chi et al. (25) determined positive correlation between PAP with 
NT-proBNP in COPD patients and Bando et al. (27) found higher 
serum BNP levels in COPD patients with PH than COPD patients 
without PH. Leuchte et al. (23) showed significant correlation 
between serum BNP levels with PAP in COPD patients with 
PAP>35 mm Hg at right heart catheterization. Similar to previous 
studies we also found significant correlation between PAP with 
NT-proBNP. Based on this significant correlation, we suggest 
that NT-proBNP levels might be a prognostic and noninvasive 
marker in advance disease stages of COPD. However no signifi-
cant correlations between NT-proBNP with right ventricular 
diastolic parameters were found in the present study. These 
results could be attributed to the small sample size and limita-
tions of echocardiography (air trapping, changes of chest wall, 
etc) in COPD patients. In the literature NT-proBNP level has 
been associated with age as ventricular compliance decreases 
with age (28, 29). Similar to the previous reports relationship 
between NT-proBNP level with age was also determined in the 
present study. 
Quality of life and exercise capacity of COPD patients are 
impaired (30). Patients generally descibe exercise intolerance 
as declined response of ventilation to exercise related with 
airflow limitation (31, 32). Besides, depression and sedentary 
life style due to dyspnea are contributing factors to exercise 
intolerance (19). In our study patients with COPD had signifi-
cant exercise limitation when compared with control subjects. 
These results can be explained as the importance of inspira-
tory capacity and vital capacity in response to increased ven-
tilatory demand in COPD patients during exercise. 
Several studies have shown exercise limitation in left ven-
tricular dysfunction (22, 33, 34). Kruger et al. (34) have also 
found negative correlation between serum BNP level with 
PVO2 and AT values in 70 patients with congestive heart failure. 
Eroğlu et al. (35) evaluated the relationship between BNP lev-
els and CPET parameters in patients with dyspnea and isolated 
left ventricle diastolic dysfunction and found negative correla-
tion between BNP levels and duration of exercise, AT VO2, and 
MET on CPET. To the best of our knowledge, this is the first 
study using CPET, and BNP levels in COPD patients. In the 
present study, NT-proBNP was negatively correlated with AT 
VO2, AT VCO2 and PVO2 values. Thus serum NT-proBNP levels 
can be regarded as a useful biomarker in exercise limitation of 
moderate-severe COPD patients. 
Limited number of studies investigating the effects of dia-
stolic dysfunctions on exercise capacity in COPD patients was 
found. Cuttica et al. (36) determined significant association 
between right sided cardiac structural changes with exercise 
capacity in COPD patients. In the present study, exercise capac-
ity was also affected by diastolic dysfunctions and PH. Although 
serum NT-proBNP level was not correlated with right ventricle 
parameters, serum NT-proBNP level was significantly higher in 
COPD patients than control subjects and right ventricle diastolic 
and systolic dysfunction was seen in COPD patients and signifi-
cant relationships between serum NT-proBNP and CPET param-
eters were found. 
We also demonstrated the correlations between SF-36 
domains with pulmonary function test results and positive corre-
lations between SF-36 domains with PVO2 and AT values consis-
tent with the literature (19, 37, 38). However we did not find rela-
tionship between PH and quality of life. These results might be 
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due to characteristics of our study population as COPD patients 
had mild PH. Improvement of quality of life will help to increase 
exercise capacity in COPD patients. Moreover significant correla-
tion between serum NT-proBNP and role limitation due to physi-
cal disorder may indicate the utility of serum NT-proBNP to dem-
onstrate quality of life in COPD patients. These preliminary results 
should be validated and explored in further studies. 
Study limitations
We used echocardiographic assessments however technical 
difficulties due to hyperinflation can be seen in COPD patients. 
Right heart catheterization- gold standart diagnostic tool for 
right ventricular dysfunction and PH- could not be performed to 
our study population. Small sample size is another limitation of 
the present study. 
Conclusion
Right ventricular dysfunction contribute exercise limitation 
together with airflow obstruction in moderate and severe COPD 
patients. Serum NT-proBNP levels can be used to demonstrate exer-
cise capacity and quality of life in COPD patients. Further studies are 
needed to validate and explore these preliminary results in larger 
number of moderate and severe COPD patients with right ventricular 
dysfunction confirmed diagnosis with right heart catheterization.
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